RASolute 302: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator s Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Brief description of study

This study is being done to find out if the treatment RMC-6236 can help patients with advanced pancreatic cancer live longer or keep their cancer from growing compared to standard chemotherapy chosen by the doctor. Patients in the study will be randomly placed into two groups: one group will get RMC-6236, and the other group will get one of four common chemotherapy treatments. Doctors will decide which chemotherapy treatment is best for each patient before the study starts. Patients will be grouped based on their activity level, whether their cancer spread right away, if they have liver tumors, and the type of RAS gene mutation in their cancer. The study has three parts: Screening (to check if a patient qualifies), Treatment (which continues until the patient stops for medical or other reasons), and Follow-up (to track health and survival after treatment ends). Scans to check tumor growth will be done every 8 weeks. The main goal is to see if RMC-6236 helps patients live longer or delays cancer growth compared to chemotherapy.


Clinical Study Identifier: s24-00876
ClinicalTrials.gov Identifier: NCT06625320
Principal Investigator: Paul E. Oberstein.
Other Investigators: Daniel J Becker, Marta Wioleta Wronska, Jennifer Chuy, Kristen Spencer, Monica Rivera, Keriann M Scavone, Nina Beri, Anastasiya Apanasyuk, Michael Shusterman, Rafael Winograd, Shun Yu, Alexander A Hindenburg.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.